Pfizer Signs Multiyear Agreement to Make Gilead’s Remdesivir
Pfizer announced today (8/7) that it has signed a multiyear agreement for Gilead’s remdesivir, a treatment for COVID-19. With Gilead aiming to produce enough remdesivir to treat more than 2 million patients by the end of the year, and agreeing to send...
FDA Issues EUA for Vela Diagnostics COVID-19 PCR Test
The FDA issued yesterday (8/5) Emergency Use Authorization for Vela Diagnostics for the manual version of their COVID-19 PCR test. The manual version of the test enables flexible sample processing, facilitating widespread use of the test throughout the United States....
FDA Approves of RedHill Pharma Phase 3 Study for NTM Infections
The FDA approved today of (7/31) RedHill Biopharma’s, a specialty pharmaceutical company headquartered in Israel, investigational new drug (IND) application for phase 3 of RHB-204 in adults with pulmonary nontuberculous myobacteria (NTM) disease....
US House of Representatives Approves $3.2 Billion for FDA Budget
The US House of Representatives approved of a $3.2 billion budget for the FDA for the 2021 fiscal year, a $40.8 million increase from the 2020 fiscal year. The additional funding is meant to support new initiatives for greater collaboration across departments within...
US Government to Pay Pfizer and BioNTech Almost $2 Billion
The US government will pay American pharmaceutical leader Pfizer and German biotech BioNTech $1.95 billion USD to buy enough COVID-19 vaccines for approximately 50 million people. Pfizer and BioNTech will not receive payment until their...
Novartis Receives Approval For Enzair Breezhaler
The European Commission (EC) has granted approval for Novartis’ Enzair Breezhaler, a drug therapy for uncontrolled asthma. The drug is utilized as a maintenance treatment for adults with asthma. “Novartis is working to reimagine medicine for people with uncontrolled...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com
